Pediatric Vaccines

Infanrix hexa maker to increase supply of vaccine

Published in Vaccine Weekly, October 19th, 2005

GlaxoSmithKline, plc, (GSK) announced that it would be significantly increasing supplies of its Infanrix hexa (Diphtheria-Tetanus-Acellular Pertussis (DTPa), hepatitis B (hep B), Inactivated Polio Vaccine (IPV), Haemophilus Influenza Type B (Hib)) pediatric combination vaccine.

According to the company, the move is designed to ensure children do not go unvaccinated after the recommendation from the European Medicines Agency (EMEA) to suspend the marketing authorization for Hexavac vaccine (DTPa, hep B, IPV, Hib) from Sanofi Pasteur, MSD, as a precautionary measure.

GSK's Infanrix hexa differs significantly from Hexavac and is not impacted by this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry